Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Mallinckrodt public limited company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment provides Acthar, an injectable biopharmaceutical drug for use in various indications, including neurology, rheumatology, nephrology, and pulmonology; Ofirmev and Xartemis XR for pain indications; EXALGO extended-release tablets to treat chronic pain; and GABLOFEN injections for use in the management of spasticity of cerebral or spinal origin. It also offers generics and active pharmaceutical ingredients (API), such as hydrocodone and hydrocodone-containing tablets, oxycodone and oxycodone-containing tablets, and methylphenidate HCl extended-release tablets, as well as biologics, medicinal opioids, synthetic controlled substances, acetaminophen products, and other active ingredients. The Global Medical Imaging segment provi
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||39.32%||Sales Growth - Q/Q||5.03%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-1.44%||ROE||-3.57%||ROI||-1.9%|
|Current Ratio||2.86||Quick Ratio||2.41||Long Term Debt/Equity||2.75||Debt Ratio||0.15|
|Gross Margin||50.09%||Operating Margin||-4.3%||Net Profit Margin||-5.75%||Dividend Payout Ratio|
|Cash From Financing Activities||40.6 M||Cash From Investing Activities||-53 M||Cash From Operating Activities||365.5 M||Gross Profit||488.5 M|
|Net Profit||98.8 M||Operating Profit||95.2 M||Total Assets||12.81 B||Total Current Assets||2.22 B|
|Total Current Liabilities||775.7 M||Total Debt||3.99 B||Total Liabilities||7.63 B||Total Revenue||909.9 M|
|High 52 week||36.08||Low 52 week||11.99||Last close||22.46||Last change||1.22%|
|RSI||74.56||Average true range||0.75||Beta||1.34||Volume||1.2 M|
|Simple moving average 20 days||8.28%||Simple moving average 50 days||10.45%||Simple moving average 200 days||-3.26%|
|Performance Week||5.69%||Performance Month||30.51%||Performance Quart||-16.19%||Performance Half||-7.07%|
|Performance Year||30.13%||Performance Year-to-date||42.15%||Volatility daily||2.21%||Volatility weekly||4.94%|
|Volatility monthly||10.12%||Volatility yearly||35.05%||Relative Volume||178.31%||Average Volume||2.26 M|
|New High||New Low|
2019-03-22 09:30:01 | Is Mallinckrodt public limited MNK Stock Outpacing Its Medical Peers This Year?
2019-03-22 09:10:01 | Is Mallinckrodt MNK Stock Undervalued Right Now?
2019-03-21 17:45:09 | Mallinckrodt MNK Gains But Lags Market: What You Should Know
2019-03-19 11:51:03 | Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients
2019-03-19 11:49:03 | Top Ranked Value Stocks to Buy for March 19th
2019-03-18 06:45:00 | Bryan Reasons Joins Mallinckrodt as the Company's Chief Financial Officer CFO
2019-03-13 06:30:00 | Look Out for Big Pharma Credit Downgrades This Year
2019-03-12 09:55:01 | Is Mallinckrodt MNK a Great Stock for Value Investors?
2019-03-11 13:13:34 | Opioid litigation concerns weigh on pharmaceutical loan borrowers
2019-03-11 10:31:05 | What Could Drive Mallinckrodt’s Growth in Fiscal 2019
2019-03-11 09:55:01 | Add These 6 Low P/B Stocks to Your Portfolio in March
2019-03-11 09:00:57 | Comparing Endo’s and Mallinckrodt’s Gross Margin Forecasts
2019-03-11 07:31:56 | How Endo’s and Mallinckrodt’s Expense Control Stacks Up
2019-03-08 14:40:02 | Endo International’s and Mallinckrodt’s EPS Growth Expectations
2019-03-08 13:10:02 | Comparing Endo’s and Mallinckrodt’s Revenue Forecasts
2019-03-08 11:37:59 | Analysts’ Views on Endo International and Mallinckrodt
2019-03-08 09:30:02 | MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
2019-03-06 09:15:02 | Stocks Get Stuck Waiting for Trade Deal
2019-03-05 11:16:44 | OxyContin Maker Purdue Pharma's Legal Entanglement, Explained
2019-03-04 06:55:00 | Mallinckrodt Presents New Data on Real-World Resource Utilization Associated with Continuation of Systemic Treatment among Patients with Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting
2019-02-27 15:30:08 | Mallinckrodt MNK Rallies as Earnings Beat Estimates in Q4
2019-02-27 08:32:01 | Implied Volatility Surging for Mallinckrodt MNK Stock Options
2019-02-26 16:11:09 | This Pharma Stock Is Making A Bullish Run After Crushing Earnings Views
2019-02-26 15:51:59 | Edited Transcript of MNK earnings conference call or presentation 26-Feb-19 1:30pm GMT
2019-02-26 15:11:10 | Mallinckrodt PLC MNK Q4 2018 Earnings Conference Call Transcript
2019-02-26 14:30:00 | Here's Why Mallinckrodt Jumped as Much as 26.8% Today
2019-02-26 11:18:00 | Mallinckrodt stock up 14% on earnings beat
2019-02-26 07:58:30 | Stocks making the biggest moves premarket: Home Depot, Caterpillar, Tesla & more
2019-02-25 13:41:02 | Mallinckrodt's Q4 Earnings Preview
2019-02-22 09:21:02 | What's in the Cards for Perrigo PRGO This Earnings Season?
2019-02-21 09:15:02 | Another Round of Slight Gains Amid Choppy Session
2019-02-21 07:21:12 | 6 Low Price-to-Book Stocks for Value Investors
2019-02-21 03:00:00 | Mallinckrodt Announces Interim Analysis Results for TherakosR Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease
2019-02-20 15:09:08 | Mylan MYL to Report Q4 Earnings: What's in the Offing?
2019-02-20 06:55:00 | Mallinckrodt Announces Interim Analysis Results for Therakos® Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease
2019-02-19 17:47:10 | Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
2019-02-18 08:16:01 | What's in the Cards for Amarin AMRN This Earnings Season?
2019-02-15 16:08:09 | What's in the Cards for Bausch Health BHC Q4 Earnings?
2019-02-13 09:30:02 | MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
2019-02-12 06:55:00 | Mallinckrodt To Present At Barclays Global Healthcare Conference
2019-02-11 15:58:08 | Is a Disappointment in Store for Incyte INCY Q4 Earnings?
2019-02-08 17:13:10 | Teva TEVA to Report Q4 Earnings: What's in the Cards?
2019-02-08 16:56:09 | Tilray TLRY to Report Q4 Earnings: What's in the Cards?
2019-02-08 08:03:15 | See what the IHS Markit Score report has to say about Mallinckrodt Plc.